Pipeline

We are developing product candidates that leverage our T-win® vaccine technology platform to modulate the TME and improve tumor cell killing.

Pipeline

We are developing product candidates that leverage our T-win® platform to generate immune-modulatory, off-the-shelf therapeutic cancer vaccines designed to kill both tumor cells and immune-suppressive cells in the TME and improve tumor cell killing in multiple cancer indications.

IO Biotech Pipeline

Cylembio® (imsapepimut and etimupepimut, adjuvanted)
* In combination with pembrolizumab; NSCLC, non-small cell lung cancer, PFS, progression-free survival; SCCHN, squamous cell carcinoma of the head and neck; IOB-013: ClinicalTrials.gov: NCT05155254; IOB-022: ClinicalTrials.gov: NCT05077709; IOB-032: ClinicalTrials.gov: NCT05280314